Xcout Intel
ARTHEx Biotech
ARTHEx Biotech S.L. is a spin-off company of the University of Valencia dedicated to developing advanced RNA-based treatments against genetic diseases. The company maintains its headquarters in Paterna and Valencia, Spain.
Subscribe to see ARTHEx Biotech’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
ARTHEx Biotech at a glance
ARTHEx Biotech is a biotechnology company headquartered in Spain. It has raised at least $91.8M across the 2 funding rounds on record. Its most recent funding round, Series B, raised $87M in September 2025. Xcout tracks 12 named people at ARTHEx Biotech, including Frédéric Legros (Executive Chairman & Chief Executive Officer).
ARTHEx Biotech leadership
- Frédéric LegrosExecutive Chairman & Chief Executive Officer
- Beatriz LlamusíChief Scientific Officer & Co-Founder
- Pedro FernándezDirector of Operations
- Glenn SblendorioIndependent Chairman of the Board
- Alain HuriezBoard Member
- Andreas SchmidtBoard Member
6 more named people on record for ARTHEx Biotech, with roles, board committees and tenure — see the full roster →
ARTHEx Biotech funding rounds
At least $91.8M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $87M | 9 named | |
| — | $4.8M | 10 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
ARTHEx Biotech competitors
A few of ARTHEx Biotech's closest competitors — see the full list of competitors and alternatives →
ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company located in San Diego, California. The company is committed to developing cutting-edge RNA-targeted therapeutics to treat various genetic and severe diseases. ADARx focuses on translating scientific research into life-saving medicines through its proprietary drug discovery pipeline.
Averna Therapeutics is a biotechnology company developing genomic medicines utilizing RNA and lipid nanoparticle technologies. The company focuses on safe and efficient gene insertion and the treatment of rare genetic diseases through research and development teams located in Boston and Israel.
Aptadir Therapeutics is a biotechnology company based in Milan, Italy, specializing in the development of RNA inhibitor-based therapeutics. The firm focuses on creating novel treatments for intractable cancers and genetic disorders.
Phlox Therapeutics is a private biotechnology company pioneering RNA-based gene therapies to alleviate and cure severe genetic heart diseases and cardiomyopathies. Headquartered in Naarden, Netherlands, the company focuses on innovative cardiovascular treatments.
DTx Pharma, Inc. is a privately held biotechnology company based in San Diego, California, that addresses the challenges associated with delivering RNA-based therapeutics.
Theranexus (THX Pharma) is a clinical-stage biopharmaceutical company that develops innovative therapeutic solutions for patients suffering from rare neurological diseases such as Batten disease, Niemann-Pick type C, and Gaucher disease. The company utilizes scientific research and antisense oligonucleotides to create targeted drug candidates addressing significant unmet medical needs.
Get ARTHEx Biotech's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on ARTHEx Biotech in Xcout Intel
- 12 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access